Incyte, a large-cap None stock, moved -0.6% this evening. Here are some facts about the company that we're keeping an eye on:
-
Incyte has logged a -35.0% 52 week change, compared to 14.0% for the S&P 500
-
INCY has an average analyst rating of buy and is -27.4% away from its mean target price of $74.41 per share
-
Its trailing earnings per share (EPS) is $1.88, which brings its trailing Price to Earnings (P/E) ratio to 28.7. The Health Care sector's average P/E ratio is None
-
The company's forward earnings per share (EPS) is $4.52 and its forward P/E ratio is 12.0
-
The company has a Price to Book (P/B) ratio of 2.45 in contrast to the Health Care sector's average P/B ratio is None
-
INCY has reported YOY quarterly earnings growth of 52.0% and gross profit margins of 0.5%
-
The company's free cash flow for the last fiscal year was $554.59 Million and the average free cash flow growth rate is 13.3%
-
Incyte's revenues have an average growth rate of 10.3% with operating expenses growing at None%. The company's current operating margins stand at 19.0%